A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
maximum tolerated dose
1-3 months
Yes
Geoffrey Shapiro, M.D.
Principal Investigator
Dana-Farber Cancer Institute
United States: Food and Drug Administration
CYC682-07
NCT00999401
February 2009
September 2012
Name | Location |
---|---|
Dana Farber Cancer Institute | Boston, Massachusetts 02115 |